- Biotech company Next Science (NXS) has received CE Mark approval for its BlastX product
- This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom
- BlastX an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing
- It used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores
- The CE Mark a minimum requirement for many other jurisdictions so we can now work on further approvals
- Next Science has ended the day 9.7 percent in the green with shares trading at $1.30
